Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy

Table 3 Patient and treatment characteristics by high-risk cohort

Characteristic	All patients (n = 547)		FHR (n = 225)		UHR (n = 92)		vHigh Risk (n = 126)		FHR vs. UHR p-value
Characteristic		%		%		%		%	FHR vs. UHR p-value
Age (years)
Median	67.0		67.4		68.4		67.2		278
Range	46–83		47–83		46–80		48–81
T Stage (no.)									<.0005
T1b–T2a	132	24	78	35	10	11	0	0
T2b–T2c	121	22	51	23	10	11	0	0
T3a	168	31	96	43	72	78	0	0
T3b-T4	126	23	0	0	0	0	126	100
PSA (μg/L)									<.0005
Median	14.5		14.1		22.5		14.9
Mean	20.2		18.3		31.2		21.9
Range	0.6–263		0.6–69		1.8–263		1.2–127
PSA Group (no.)									<.0005
< 10 μg/L (no.)		28		33		17	37	29
10–20 μg/L	151	38	74	34	16	10	44	35
(no.)	209	34	76	33	9	73	45	36
≥ 20 μg/L (no.)	187		75		67
Gleason Score (No.)									<.0005
<7	147	27	80	36	11	12	50	40
=7	250	46	91	40	24	26	37	29
>7	150	27	54	24	57	62	39	31
Radiation dose
Median (Gy)	74.0		74.0		74.0		70.0		.082
Radiation technique									.123
3D–CRT	432	79	170	76	61	66	112	89
IMRT	115	21	55	24	31	34	14	11
Duration of ADT
Median (months)	8.0		8.0		13.5		8.0		.102
Mean (months)	14.9		16.4		20.8		13.7
Range (months)	0–72		0–53		4–72		0–68
Duration of ADT (no)
None (no.)	11	2	4	2	0	0	1	1
1–6 months (no.)	181	32	69	31	24	26	44	35
7–12 months (no.)	195	34	74	33	22	24	50	40
13–24 months (no.)	10	2	3	1	4	4	2	2
>24 months (no.)	150	29	75	33	42	46	29	23

Abbreviations: FHR favourable high risk, UHR unfavourable high risk, PSA prostate-specific antigen, ADT androgen deprivation therapy, 3D–CRT three dimensional conformal radiotherapy, IMRT intensity-modulated radiation therapy

ISSN: 1471-2490